Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03625648 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pentoxifylline in Diabetic Kidney Disease

Study acronym: VA PTXRx
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv23
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 2510 to confirmed 2376 · Study sites: 35 to 34v22 Show 2 more changesShow less
    • Enrollment target: estimated 2510 to confirmed 2376
    • Study sites: 35 to 34
  3. Site details revised at 8 of 35 sitesv21
  4. Eligibility criteria expanded, about 30 words Site details revised at 1 of 35 sitesv20 Show 1 more changeShow less
    • Site details revised at 1 of 35 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites revised (35)v19 See this version in full on ClinicalTrials.gov ↗
Show 17 earlier versionsHide 17 earlier versions
  1. Site details revised at 2 of 35 sitesv18
  2. Study sites: 25 to 35v17
  3. Study sites: 16 to 25 Eligibility criteria expanded, about 82 wordsv16 Show 1 more changeShow less
    • Eligibility criteria expanded, about 82 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study description shortened, about 105 words Site details revised at 2 of 16 sitesv15 Show 1 more changeShow less
    • Site details revised at 2 of 16 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 6 to 16v14
  6. Site details revised at 1 of 6 sitesv13
  7. Study description expanded, about 18 words Site details revised at 3 of 6 sitesv12 Show 1 more changeShow less
    • Site details revised at 3 of 6 sites

    See this version in full on ClinicalTrials.gov ↗

  8. Trial status: Active, Not Recruiting to Recruiting Study description expanded, about 40 words · Site details revised at 6 of 6 sitesv11 Show 2 more changesShow less
    • Study description expanded, about 40 words
    • Site details revised at 6 of 6 sites

    See this version in full on ClinicalTrials.gov ↗

  9. Study description expanded, about 45 wordsv10 See this version in full on ClinicalTrials.gov ↗
  10. Trial status: Recruiting to Active, Not Recruiting Site details revised at 6 of 6 sitesv9 Show 1 more changeShow less
    • Site details revised at 6 of 6 sites
  11. Secondary endpoints revised (7) Site details revised at 4 of 6 sites · Eligibility criteria shortened, about 1 wordv8 Show 2 more changesShow less
    • Site details revised at 4 of 6 sites
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  12. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 1, 2019 to Nov 18, 2019 · Site details revised at 6 of 6 sitesv7 Show 2 more changesShow less
    • Start date changed from estimate of Nov 1, 2019 to Nov 18, 2019
    • Site details revised at 6 of 6 sites
  13. Start date: Oct 1, 2019 to Nov 1, 2019 Study sites: 1 to 6v6 Show 1 more changeShow less
    • Study sites: 1 to 6
  14. Eligibility criteria expanded, about 1 wordv5 See this version in full on ClinicalTrials.gov ↗
  15. Start date: Sep 9, 2019 to Oct 1, 2019v4
  16. Start date: Jun 3, 2019 to Sep 9, 2019v3
  17. Start date: Jan 2, 2019 to Jun 3, 2019v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Trial Details
NCT Number NCT03625648
Lead Sponsor VA Office of Research and Development
Conditions Diabetic Kidney Disease
Enrollment 2,376 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov